Answers are grounded in this paper and cite their sources.
SUMMARY In recent years some new antithrombotics have been studied or in part licensed, which have proven to be highly effective and, therefore, may replace the well‐known anticoagulants such as unfractionated heparin, low‐molecular‐weight heparin and warfarin in the future. The purpose of this review is to provide an introduction to the pharmacologic profile and clinical indications of the new direct thrombin inhibitors bivalirudin, argatroban, ximelagatran as well as the indirect factor Xa (FXa) inhibitors fondaparinux and idraparinux. In particular, this article focuses on implications for the safe use of these new agents in surgery and anesthesia, and discusses therapeutic options for drug‐induced bleeding.
No takes yet. Share an insight, caveat, or question.
Heymann et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: